Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and...

Area of Science:

• Hematology
• Immunology
• Translational Medicine

Background:

• Autoimmune heparin-induced thrombocytopenia (aHIT) is a severe immune-mediated thrombocytopenia linked to anti-platelet factor 4 (PF4) antibodies.
• aHIT causes both thrombocytopenia and thrombosis independently of heparin, with limited evidence-based treatments.
• Understanding shared pathogenic pathways with immune thrombocytopenia (ITP) and antiphospholipid syndrome (APS) is crucial for aHIT management.

Purpose of the Study:

• To review and integrate mechanistic and therapeutic insights from ITP and APS to inform aHIT treatment strategies.
• To identify shared central drivers of platelet activation and clearance in aHIT.
• To explore the potential of targeted immunomodulatory therapies for aHIT.

Main Methods:

• Narrative translational review of literature from 2015-2025.
• Searched PubMed, Scopus, Web of Science, and ClinicalTrials.gov.
• Focused on FcγRIIa-Syk-BTK signaling and complement activation pathways.

Main Results:

• FcγRIIa-Syk-BTK signaling and complement activation are identified as key drivers in aHIT.
• Preclinical and clinical data suggest Syk inhibitors (fostamatinib), BTK inhibitors (rilzabrutinib, zanubrutinib), and complement inhibitors (sutimlimab) show therapeutic potential.
• These targeted interventions may restore platelet counts and reduce immune-driven thrombosis.

Conclusions:

• Pathway-specific interventions targeting Syk, BTK, and complement hold significant therapeutic potential for aHIT.
• Biomarker-guided translational trials are needed to validate the efficacy and safety of these treatments.
• Integrating knowledge from ITP and APS provides a framework for precision immunotherapy in aHIT.